Handelsbanken Fonder’s Recursion Pharmaceuticals RXRX Stock Holding History

Handelsbanken Fonder’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$763K	Buy	207,900 +99,000	+91%	+$330K	﹤0.01%	1247
2026 Q1	$334K	Hold	108,900	–	–	﹤0.01%	1392
2025 Q4	$445K	Buy	108,900 +20,200	+23%	+$100K	﹤0.01%	1336
2025 Q3	$433K	Hold	88,700	–	–	﹤0.01%	1318
2025 Q2	$449K	Buy	88,700 +15,100	+21%	+$74.2K	﹤0.01%	1292
2025 Q1	$389K	Hold	73,600	–	–	﹤0.01%	1326
2024 Q4	$498K	Buy	73,600 +4,100	+6%	+$27.6K	﹤0.01%	1297
2024 Q3	$458K	Buy	69,500 +17,400	+33%	+$125K	﹤0.01%	1282
2024 Q2	$391K	Buy	52,100 +18,000	+53%	+$157K	﹤0.01%	1272
2024 Q1	$340K	Hold	34,100	–	–	﹤0.01%	1338
2023 Q4	$336K	Buy	34,100 +11,700	+52%	+$83.4K	﹤0.01%	1338
2023 Q3	$171K	Hold	22,400	–	–	﹤0.01%	1500
2023 Q2	$167K	Buy	22,400 +3,600	+19%	+$25.2K	﹤0.01%	1525
2023 Q1	$125K	Hold	18,800	–	–	﹤0.01%	1512
2022 Q4	$145K	Buy	18,800 +5,500	+41%	+$53.9K	﹤0.01%	1479
2022 Q3	$142K	Hold	13,300	–	–	﹤0.01%	1488
2022 Q2	$108K	Hold	13,300	–	–	﹤0.01%	1573
2022 Q1	$95K	Hold	13,300	–	–	﹤0.01%	1686
2021 Q4	$228K	Buy	+13,300	New	+$250K	﹤0.01%	1678

Other funds holding RXRX

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Carroll Investors Mt Pleasant, South Carolina $234M AUM 59.79% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Allen Operations New York $722M AUM 20.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Handelsbanken Fonder's RXRX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Recursion Pharmaceuticals (RXRX) stake by 91% in Q2 2026, buying an estimated $330K and bringing the position to 207,900 shares worth $763K. The position accounts for ﹤0.01% of the portfolio, ranked #1247.

Handelsbanken Fonder first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. 124 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Handelsbanken Fonder held 207,900 shares of Recursion Pharmaceuticals worth $763K as of Q2 2026.
Handelsbanken Fonder bought 99,000 Recursion Pharmaceuticals shares in Q2 2026, an estimated $330K.
Recursion Pharmaceuticals made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1247 holding.
Handelsbanken Fonder first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
124 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.